Disease | tuberous sclerosis |
Comorbidity | C0004114|astrocytomas |
Sentences | 27 |
PubMedID- 23158522 | We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex. |
PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
PubMedID- 21047224 | Background: neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. |
PubMedID- 24105488 | Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention. |
PubMedID- 25493579 | The pathogenic activation of mtorc1 leads to the development of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
PubMedID- 25557360 | Background: the aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mtor) inhibitor, of subependymal giant cell astrocytomas (sega) in patients with tuberous sclerosis complex (tsc). |
PubMedID- 24667738 | The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. |
PubMedID- 23158521 | Everolimus for astrocytomas in tuberous sclerosis complex. |
PubMedID- 24056156 | Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. |
PubMedID- 24192699 | Equally important avenues of molecular investigation might include inhibiting disease-causing pathways, such as the proposed use of rapamycin for subependymal giant cell astrocytomas in children with tuberous sclerosis;(83) upregulating affected proteins from homologous genes as in models of spinal muscular atrophy (84); or counteracting the downstream effects of a deficient protein, such as the proposed use of igf1 in children with duchenne’s dystrophy [for review, please see liew, 2012 (85)]. |
PubMedID- 23231513 | In patients with subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce sega volume with good tolerability. |
PubMedID- 25002765 | The variety of astrocytomas commonly associated with tuberous sclerosis is the sega with incidences ranging from 6% to 16%. |
PubMedID- 20643042 | Objective: presentation of 8 patients with subependymal giant-cell astrocytomas (sgca) associated with tuberous sclerosis complex (tsc). |
PubMedID- 23582392 | Everolimus for astrocytomas in tuberous sclerosis. |
PubMedID- PMC3518234 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
PubMedID- 21792104 | Mtor inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. |
PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
PubMedID- 23743818 | Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis. |
PubMedID- 23548133 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
PubMedID- 23582393 | Everolimus for astrocytomas in tuberous sclerosis - author's reply. |
PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
PubMedID- 26137524 | Everolimus has since also been fda-approved for neuroendocrine tumors of pancreatic origin (pnet), breast carcinoma, and subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis. |
PubMedID- 22647206 | Areas covered: the objective of this review is to discuss the history of key findings and innovative cancer research undertaken to successfully develop everolimus as an oncology therapy (afinitor) now approved for patients with advanced renal cell carcinoma (rcc) and for subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis. |
PubMedID- 21306252 | Everolimus and giant-cell astrocytomas in tuberous sclerosis. |
PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
PubMedID- 21306253 | Everolimus and giant-cell astrocytomas in tuberous sclerosis. |
Page: 1